Tevogen Bio (TVGNW) Stock Price, News & Analysis

Company Overview

Tevogen Bio is a clinical-stage biotechnology company focused on developing allogeneic T cell receptor (TCR)-based immunotherapies for the treatment of cancer and infectious diseases. Leveraging a proprietary platform of engineered T cells, the company aims to deliver off-the-shelf cellular products that can recognize and eliminate disease-specific antigens without the need for patient-matched cell manufacturing.

The company’s pipeline encompasses programs targeting chronic viral infections, including hepatitis B virus and SARS-CoV-2, as well as cytomegalovirus, alongside oncology indications such as solid and hematological tumors. Tevogen Bio has advanced multiple candidate therapies into preclinical studies and early-phase clinical trials, evaluating safety, dosing strategies and preliminary efficacy across diverse patient populations.

Originating from translational immunology research at the Sheba Medical Center in Israel, Tevogen Bio secured exclusive rights to novel TCR technologies and subsequently established operations in the United States. The company completed a corporate transaction to become publicly listed on the Nasdaq under the ticker TVGNW, positioning it to accelerate clinical development and expand manufacturing capabilities.

Headquartered in the United States, Tevogen Bio collaborates with leading academic institutions and clinical centers worldwide to optimize its T cell engineering processes and trial designs. The company’s leadership team combines expertise in cell therapy development, translational research and regulatory affairs with a shared commitment to delivering scalable immunotherapies for patients in need.

Key Stats

• Today's Range: $0.04 to $0.05
• 50-Day Range: $0.04 to $0.06
• 52-Week Range: $0.03 to $0.08
• Volume: 114,609 shs
• Average Volume: 189,389 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TVGNW
• CIK: 1860871
• Web: tevogen.com
• Phone: 877-838-6436
• Fax: N/A
• Employees: 17
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A